Taken together, our findings shed light on the potential of concurrently targeting both epigenetic factors and receptor tyrosine kinase signaling as a promising therapeutic approach for treating FLT3-ITD AML, particularly in R/R patients. The gene discussed is FLT3; the disease is acute myeloid leukemia.